Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.67 |
| ▸ | MAOA | P21397 | 3/20 | 0.67 |
| ▸ | CALML3 | P27482 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SDHA | P31040 | 1/20 | 0.48 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4647204 | 1.00 | MAOB (0.67) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5833811 | 0.88 | F10 (0.57) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5833809 | 0.88 | F10 (0.57) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL28809356 | 0.87 | F10 (0.60) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL28809355 | 0.87 | F10 (0.60) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL5432675 | 0.85 | MAOB (0.49) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL4649482 | 0.85 | MAOB (0.49) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL11554348 | 0.84 | MAOA (0.73) | MAOBMAOACALML3GRM2 | |
| SCHEMBL4965827 | 0.83 | F10 (0.53) | MAOBMAOACALML3LMNAPTGS1 | |
| SCHEMBL27977656 | 0.83 | MAOB (0.71) | MAOBMAOACALML3LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101019825-A | Process of dissolving 3,5-substituted oxazolidone | SICHUAN BEILIKE BIOTECHNOLOGY (CN) | 2007-08-22 | — | — | CN | claimed |
| CN-104364240-B | A medicine for preventing or treating mycobacterial diseases | 四川贝力克生物技术有限责任公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-1960374-A1 | ISOLATED DESFLUORO-LINEZOLID, PREPARATION THEREOF AND ITS USE AS A REFERENCE MARKER AND STANDARD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-08-27 | — | — | EP | disclosed |
| US-20070197529-A1 | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard | TEVA PHARMACEUTICALS USA, INC. | 2007-08-23 | — | — | US | disclosed |
| CN-101019825-A | Process of dissolving 3,5-substituted oxazolidone | SICHUAN BEILIKE BIOTECHNOLOGY (CN) | 2007-08-22 | — | — | CN | disclosed |
| WO-2007064818-A1 | ISOLATED DESFLUORO-LINEZOLID, PREPARATION THEREOF AND ITS USE AS A REFERENCE MARKER AND STANDARD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197529-A1 | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard | MLLT3, DAO, FHIT | MAOB 2084/4885MAOA 1747/4885CALML3 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.